
Prior Authorization DRUG Guidelines

CALCIPOTRIOL (calcipotriene 0.005% cream) Effective

Date: 8/18/2020

Date Developed: 8/18/2020 by Dr. H. Taekman

Last Approval Date: 8/18/2020, 8/3/21, 2/1/22, 1/31/23,
2/13/24, 2/18/25

Calcipotriene is a synthetic vitamin D3 analog which regulates skin cell production and proliferation. Binds to vitamin D receptors and inhibits keratinocyte proliferation and enhances keratinocyte differentiation

Pre-Authorization Criteria:

Treatment of plaque psoriasis of the body (cream, ointment) or of the scalp (solution) in adults; treatment of plaque psoriasis of the body or of the scalp in children ≥ 12 years of age, adolescents, and adults (foam). An effective treatment when used with topical steroids. Considered first-line treatment options in pediatric patients (particularly to minimize corticosteroid exposure)

Application:

Cream, foam, ointment: Apply to affected skin twice daily; rub in gently and completely. Wash hands thoroughly after use.

Dosage Forms:

Cream, ointment External:

0.005% (60 g, 120 g) [contains cetearyl alcohol, disodium edta]

Generic: 0.005% (60 g, 120 g)

Solution, External:

Generic: 0.005% (60 mL)

Foam Generic: 0.005% (60 g)

References:

1. Feldman SR, Matheson R, Bruce S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials [published correction appears in *Am J Clin Dermatol*. 2012;13(6):422]. *Am J Clin Dermatol*. 2012;13(4):261-71. doi: 10.2165/11630710-000000000-00000.
2. Hsu S, Papp KA, Lebwohl MG, et al, "Consensus Guidelines for the Management of Plaque Psoriasis," *Arch Dermatol*, 2012, 148(1):95-102.
3. Schachner L, Hansen R, eds. *Pediatric Dermatology*. 4th ed. Philadelphia, PA: Mosby Elsevier; 2011
4. Zeichner JA, Lebwohl MG, Menter A, et al, "Optimizing Topical Therapies for Treating Psoriasis: A Consensus Conference," *Cutis*. 2010;86(3 Suppl):5-31.
5. ~~5.~~ Calcipotriene foam [prescribing information]. San Antonio, TX: Trifluent Pharma LLC; August 2020.
6. 6. Calcipotriene topical solution [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals Inc; November 2019.
7. Calcitrene ointment (calcipotriene) [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals; November 2011.
8. Simionescu AA, Danciu BM, Stanescu AMA. State-of-the-art review of pregnancy-related psoriasis. *Medicina (Kaunas)*. 2021;57(8):804
9. Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. *Dermatology*. 2021;237(2):166-178.

Revision History:

Date Developed: 8/18/2020 by Howard Taekman, MD

Date Approved by P&T Committee: August 18, 2020

Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/31/23

Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/25



VENTURA COUNTY
HEALTH CARE PLAN

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
8/18/20	NEW	Howard Taekman, MD	NEW
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated preauthorization criteria added dosage and boxed warning sections. Added references.
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Replaced vitamin "D2" with D3. Modified Dosage form section and references